(AOF) – Globus Medical is expected to rise in pre-market on Wall Street after the publication of its preliminary sales figures for the fourth quarter of 2023. The manufacturer of medical devices against musculoskeletal disorders plans to post 615 sales .5 million dollars, up more than 124% year-on-year, against a consensus of 602.3 million. Annual revenue is expected at $1.56 billion, up 53.2% year-on-year.
“2023 has been a monumental year for Globus Medica,” said boss Dan Scavilla. “We have completed our merger with NuVasive to create the most innovative technology company in the spine market. Our integration is progressing as planned and we are pleased with our sales retention to date.”
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
